Consideration of this possibility together with the evaluation of Endo180 and LOX as targets in pre-clinical models of osteolytic bone tumors induced by PC3 and DU145 cells [62–64] and predominantly osteosclerotic tumors induced by VCaP cells [65] will be prioritised in our future work. This evidence concerns the gene LOX and bone neoplasm.